MINI FUTURE LONG - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 11:27:36 21/06/2024 BST | ||
| 19.28 EUR / 19.48 EUR | +0.62% |
|
| Current month | +8.69% | ||
| 1 month | +13.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 19.3 | +0.21% |
| 20/06/24 | 19.26 | +2.99% |
| 19/06/24 | 18.7 | -0.58% |
| 18/06/24 | 18.81 | -3.39% |
| 17/06/24 | 19.47 | -3.47% |
Delayed Quote Börse Stuttgart
Last update June 21, 2024 at 08:14 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD5FPA |
| ISIN | DE000MD5FPA6 |
| Date issued | 21/06/2022 |
| Strike | 265.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.97 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.42 € |
|---|---|
| Lowest since issue | 4.26 € |
| Spread | 0.2 € |
| Spread % | 1.03% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
471.4
USD
Average target price
463.4
USD
Spread / Average Target
-1.69%
- Stock Market
- Certificates
- Certificat
